K. G. van Houwelingen

发表

High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.

J. W. Louwerenburg, M. Stoel, I. Knottnerus, 2018, International journal of cardiology.

The effect of pre‐hospital glycoprotein IIb–IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI

J. Ottervanger, C. Hamm, R. Hermanides, 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Impact of collateralisation to a concomitant chronic total occlusion in patients with ST-elevation myocardial infarction: a subanalysis of the EXPLORE randomised controlled trial

J. Tijssen, P. Laanmets, J. Piek, 2018, Open Heart.

Clinical outcome of patients with implantation of second‐generation drug‐eluting stents in the right coronary ostium: Insights from 2‐year follow‐up of the TWENTE trial

Maarten J. IJzerman, M. Stoel, C. von Birgelen, 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

New-generation drug-eluting coronary stents in octogenarians: Patient-level pooled analysis from the TWENTE I-IV trials.

M. Stoel, A. Roguin, C. von Birgelen, 2020, American heart journal.

Proximal LAD Treated With Thin-Strut New-Generation Drug-Eluting Stents: A Patient-Level Pooled Analysis of TWENTE I-III.

M. Stoel, A. Roguin, C. von Birgelen, 2020, JACC. Cardiovascular interventions.

Relationship Between Cardiovascular Risk as Predicted by Established Risk Scores Versus Plaque Progression as Measured by Serial Intravascular Ultrasound in Left Main Coronary Arteries

A. Schmermund, R. Erbel, H. Eggebrecht, 2004, Circulation.

"Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes Study.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2018, JACC. Cardiovascular interventions.

Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From the DUTCH PEERS (TWENTE II) Randomized Trial.

Maarten J. IJzerman, C. von Birgelen, G. Linssen, 2016, Revista espanola de cardiologia.

Thin, Very Thin, or Ultrathin Strut Biodegradable- or Durable-Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.

M. Stoel, C. von Birgelen, G. Linssen, 2019, JACC. Cardiovascular interventions.

Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt–chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial

M. Stoel, A. Roguin, C. von Birgelen, 2018, The Lancet.

5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2018, JACC. Cardiovascular interventions.

Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).

Maarten J. IJzerman, M. Stoel, C. von Birgelen, 2015, JACC. Cardiovascular interventions.

Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Three‐year clinical outcome in all‐comers with “silent” diabetes, prediabetes, or normoglycemia, treated with contemporary coronary drug‐eluting stents: From the BIO‐RESORT Silent Diabetes study

M. Stoel, C. von Birgelen, G. Linssen, 2019, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Final 5‐Year Report of the Randomized BIO‐RESORT Trial Comparing 3 Contemporary Drug‐Eluting Stents in All‐Comers

M. Stoel, C. von Birgelen, G. Linssen, 2022, Journal of the American Heart Association.

Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years.

M. Stoel, A. Roguin, C. von Birgelen, 2020, JACC. Cardiovascular interventions.

Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial

Maarten J. IJzerman, J. W. Louwerenburg, C. von Birgelen, 2016, Heart and Vessels.

Long‐Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer‐Generation Drug‐Eluting Stents

M. Stoel, C. von Birgelen, G. Linssen, 2018, Journal of the American Heart Association.

Value of the SYNTAX score for periprocedural myocardial infarction according to WHO and the third universal definition of myocardial infarction: insights from the TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents: A patient-level pooled analysis from TWENTE and DUTCH PEERS (TWENTE II).

Maarten J. IJzerman, M. Stoel, C. von Birgelen, 2016, American heart journal.

Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAYA study.

Maarten J. IJzerman, J. W. Louwerenburg, M. Stoel, 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial

Maarten J. IJzerman, C. von Birgelen, G. Linssen, 2015, Clinical Research in Cardiology.

Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Three‐year clinical outcome after treatment of chronic total occlusions with second‐generation drug‐eluting stents in the TWENTE trial

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): rationale and study design of the randomized TWENTE III multicenter trial.

Maarten J. IJzerman, C. von Birgelen, G. Linssen, 2014, American heart journal.

Incidence of periprocedural myocardial infarction following stent implantation: Comparison between first‐ and second‐generation drug‐eluting stents

M. Stoel, C. von Birgelen, G. Linssen, 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2018, JACC: Cardiovascular Interventions.

Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials

M. Stoel, A. Roguin, C. von Birgelen, 2020, International Journal of Cardiology.

Scanning electron microscopic assessment of the biodegradable coating on expanded biolimus-eluting stents.

C. von Birgelen, F. de Man, M. Z. Basalus, 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.